IND.244 CHU de Québec – Hôpital L’Enfant-Jésus Wednesday, May 07, 2025 The Investigational New Drug Program Team Award was presented to the IND.244 team at CHU de Québec – Hôpital L’Enfant-Jésus for their work activating and recruiting patients to this trial. Awarded at the CCTG Spring Meeting to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in a CCTG IND clinical trial to acknowledge their efforts and dedication to the success of clinical trials. "We are very grateful and pleased to receive the CCTG Investigational New Drug (IND) Team Award for our teamwork on the IND.244 study. It is an honor to see our work in initiating, activating, recruiting patients and collecting quality data for the study recognized. We feel privileged to be able to offer patients the opportunity to participate in this study, and motivated that it could open up new treatment options for central nervous system lymphoma," says the IND244 team. IND.244 is a phase II study of ibrutinib combination therapy in transplant ineligible individuals with newly diagnosed primary central nervous system lymphoma and the CHU de Québec – Hôpital L’Enfant-Jésus team includes, Philippe Nadeau, May-Lina Denis-Langlois, Émilie Gontier, Dr. Jean-Francois Larouche.
